RADNOR, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2023, after the financial markets close on Tuesday, November 7, 2023.
Tuesday, November 7th @ 4:30 p.m. ET
| Domestic: | 1-888-886-7786 |
| International: | 1-416-764-8658 |
| Conference ID: | 27015887 |
| Webcast: | Link |
If you would like a call back, please click this link, which will be made active 15 minutes prior to the scheduled start time. A live webcast of the conference call may be found here. A replay of the call will be available on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
- Primech Regains Compliance with Nasdaq’s Minimum Bid Price Requirement - May 14, 2025
- Form 8.3 – H&T Group Plc - May 14, 2025
- Silynxcom Announces Record Annual Revenue of Approximately $9.1 million in 2024 - May 14, 2025
